STOCK TITAN

PERKINELMER INC Stock Price, News & Analysis

PKI NYSE

Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.

PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.

Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.

Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.

Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.

Rhea-AI Summary

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) has declared a regular quarterly dividend of $0.07 per share. This dividend is set to be paid on November 11, 2022, to shareholders of record as of the close of business on October 21, 2022. In 2021, the company reported revenue of approximately $5 billion and employs over 16,000 people globally. PerkinElmer is committed to innovation for a healthier world and is a component of the S&P 500 Index.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
dividends
-
Rhea-AI Summary

PerkinElmer, Inc. (NYSE:PKI) has appointed Dr. Michelle McMurry-Heath to its board of directors, effective July 22, 2022. Dr. McMurry-Heath brings extensive experience in research and science policy, having served as President and CEO of the Biotechnology Innovation Organization. Her strong advocacy for equitable access to medical innovations and leadership roles at Johnson & Johnson and the FDA position her well to contribute to PerkinElmer's growth strategy post-portfolio transformation. The company reported revenues of approximately $5 billion in 2021 and continues to prioritize innovation in healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
management
-
Rhea-AI Summary

PerkinElmer, Inc. (NYSE: PKI) will release its Q2 2022 financial results on August 4, 2022, at 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, hosted by CEO Prahlad Singh and CFO Jamey Mock. The call will be accessible via a registration form on their website. A replay will be available from 10:00 a.m. ET the same day. The company reported $5 billion in revenue for 2021 and serves customers in 190 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
Rhea-AI Summary

PerkinElmer (NYSE: PKI) launched the GC 2400™ Platform, an innovative automated gas chromatography solution aimed at enhancing lab productivity and precision. Designed for pharmaceutical, food, environmental, and industrial applications, it combines systems, software, and consumables to streamline operations. Key features include automated sampling, reduced hands-on time, and a wireless touchscreen interface. Built-in sensors promote sustainability by minimizing gas consumption. The platform will be showcased at Analytica Germany and Analytica Latin America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PerkinElmer (NYSE: PKI) has launched the BioQule™ NGS System, an innovative benchtop solution for next-generation sequencing (NGS) library preparation. This system allows labs to automate the process for up to eight samples, featuring integrated quality control and liquid handling technology. Unlike existing solutions, the BioQule provides in-built quantification of created libraries and requires only 10 ng of starting material. It is suitable for various lab sizes and does not necessitate prior automation experience. The system will be showcased at the AGBT General Meeting in Orlando from June 6-9, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PerkinElmer reports Q1 2022 revenue of $1.26 billion, down from $1.31 billion a year prior. GAAP EPS from continuing operations is $1.40 compared to $3.37 in Q1 2021. The company initiates guidance for Q2 2022, forecasting revenue of $1.20-1.22 billion and expects adjusted EPS between $2.00-2.05. For the full year, expected revenue is $4.56-4.63 billion with adjusted EPS of $7.15-7.45. Despite revenue declines, the company highlights significant growth in the Discovery & Analytical Solutions segment with a 33% increase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, to be paid on August 12, 2022. This dividend is for shareholders on record as of July 22, 2022. In 2021, the company reported approximately $5 billion in revenue and employs over 16,000 individuals, serving customers across 190 countries. PerkinElmer is part of the S&P 500 Index, indicating its significant presence in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary

PerkinElmer, Inc. (NYSE: PKI) will announce its first quarter 2022 financial results after market close on May 3, 2022. The company will host a conference call that same day at 5:00 p.m. ET to discuss the results, led by CEO Prahlad Singh and CFO Jamey Mock. Investors can access the call through a live audio webcast available on the company's website, with a replay starting at 7:00 p.m. ET the same day. PerkinElmer reported approximately $5.0 billion in revenue in 2021 and operates in 190 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

PerkinElmer, Inc. (NYSE: PKI) has launched the Vega® imaging system, an innovative automated ultrasound platform aimed at enhancing preclinical research in cancer, liver and kidney diseases, and cardiology. The system allows for hands-free operation and high-throughput scanning, improving research efficiency. Key features include advanced imaging modes for better visualization of diseases and therapies. This technology was acquired through PerkinElmer's purchase of SonoVol, Inc. The company recently reported revenues near $5 billion in 2021, supporting its position in the S&P 500.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

PerkinElmer has launched two innovative no-wash assay kits, HTRF® and AlphaLISA®, aimed at detecting and quantifying CHO HCP impurities in biopharmaceutical manufacturing. These kits enhance efficiency by streamlining workflows and improving sensitivity compared to traditional methods. The assays are designed for high-throughput capabilities with the ability to process samples in 384-well plates, addressing challenges in biomanufacturing. This development supports PerkinElmer's comprehensive solutions for drug development from discovery to quality control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of PERKINELMER (PKI)?

The market cap of PERKINELMER (PKI) is approximately 14.5B.
PERKINELMER INC

NYSE:PKI

PKI Rankings

PKI Stock Data

14.46B
109.03M
0.27%
86.26%
2.79%
Diagnostics & Research
Healthcare
Link
United States
Waltham